Plasmapheresis in nephrology: An update

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 6, 2006, Pages 603-609

  Rahman, Tahmina ^a   Harper, Lorraine ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ABO incompatible transplant; ANCA associated vasculitis; Highly sensitized; Myeloma; Plasmapheresis; Thrombotic thrombocytopaenic purpura

Indexed keywords

CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; VON WILLEBRAND FACTOR;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; BLOOD GROUP ABO INCOMPATIBILITY; CHOREA MINOR; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; EATON LAMBERT SYNDROME; FAMILIAL HYPERCHOLESTEROLEMIA; GLOMERULUS BASEMENT MEMBRANE; GUILLAIN BARRE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LUNG HEMORRHAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MYASTHENIA GRAVIS; MYELOMA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PURPURA; REVIEW; SPLENECTOMY; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; WEGENER GRANULOMATOSIS;

HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEPHROLOGY; PLASMA EXCHANGE; PLASMAPHERESIS;

EID: 33750208354     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000247503.87162.15     Document Type: Review

References (72)

1. Lockwood CM, Worlledge S, Nicholas A, et al. Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med 1979; 300:524-530.
2. Hagen E, Daha M, Hermans J, et al. Diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53:743-753.
3. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
4. Huugen D, Xiao H, van Esch A, et al. Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167:47-58. This study provided further evidence that ANCA are pathogenic and that lipopolysaccharide aggravates disease severity.
5. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106:2050-2058. This model of ANCA-associated vasculitis describes how ANCAs are pathogenic. This model differs from that of Xaio et al. [3] in that it is truly autoimmune.
6. Little MA, Bhangal G, Smyth CL, et al. Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17:160-169.
7. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
8. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41:776-784.
9. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9:842-852.
10. Cole E, Cattran D, Magil A, et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20:261-269.
11. Pusey CD, Rees AJ, Evans DJ, et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40:757-763.
12. Glockner WM, Sieberth HG, Wichmann HE, et al. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multicenter study. Clin Nephrol 1988; 29:1-8.
13. Jayne DRW, Gaskin G, Rasmussen N, et al. Randomised trial of plasma exchange versus methyl prednisolone for severe renal vasculitis. N Engl J Med (in press).
14. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
15. Jayne DRW, Marshall PD, Jones S, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990; 37:965-970.
16. Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of antiglomerular- basement-membrane antibodies. Nephron Clin Pract 2003; 94:c59-c68.
17. Short AK, Esnault VL, Lockwood CM. Antineutrophil cytoplasm antibodies and antiglomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulo-nephritis. Am J Kidney Dis 1995; 26:439-445.
18. Rutgers A, Slot M, van Paassen P, et al. Coexistence of antiglomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253-262. This study compared the renal outcome of patients who have rapidly progressive glomerulonephritis with anti-GBM antibodies, anti-MPO ANCA or dual positives.
19. Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535-1540.
20. Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004; (1):CD002922. This Cochrane Review reviews treatment of lupus nephritis in an evidence-based manner and concludes there is no role for plasmapheresis in the treatment of lupus nephritis.
21. Tyden G, Kumlien G, Genberg H, et al. The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplantation 2006; 13:105-107. This study suggested that blood-group incompatible renal transplantations can be performed with standard immunosuppression and without splenectomy when using immunoadsorption and one dose of rituximab and intravenous immunoglobulin each. Excellent short and long-term results are achieved.
22. Gloor JM, Lager DJ, Fidler ME, et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572-1577. This further study also suggested that splenectomy is not required as part of a desensitization protocol in ABO-incompatible transplantation.
23. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315-1322.
24. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089-1096.
25. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635-640.
26. Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42:88-91.
27. Bryan CF, Nelson PW, Shield CF 3rd, et al. Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate. Clin Transpl 2004; 127-133.
28. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971-977.
29. Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70:1331-1335.
30. Shimmura H, Tanabe K, Ishida H, et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005; 80:985-988.
31. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145-148.
32. Futagawa Y, Terasaki PI. ABO incompatible kidney transplantation: an analysis of UNOS Registry data. Clin Transplant 2006; 20:122-126.
33. Rydberg L, Bengtsson A, Samuelsson O, et al. In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transpl Int 2005; 17:666-672.
34. Ishida H, Tanabe K, Ishizuka T, et al. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier. Transpl Int 2005; 18:716-720. It is unclear why recurrence of antibodies does not result in rejection; this has been termed accommodation. This study provided some insights into the biology of accommodation.
35. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70:1531-1536.
36. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887-895.
37. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017-1023.
38. Kayler LK, Colombe B, Farber JL, et al. Successful living donor renal transplantation despite ABO incompatibility and a positive crossmatch. Clin Transplant 2004; 18:737-742.
39. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6:459-466. This is an excellent review of the mechanism of action of IVIG in desensitizing highly sensitized transplant recipients.
40. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758-760.
41. Jordan SC, Vo AA, Nast CC, Tyan D. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience. Clin Transpl 2003; 193-198.
42. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256-3262.
43. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346-351. This retrospective study raised questions as to what desensitization protocol should be used and highlights the need for a randomized controlled trial.
44. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348:1208-1211.
45. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79:696-701. This interesting paper suggests that immunoadsorption can be used to render highly sensitized patients crossmatch negative, thereby increasing the potential for highly sensitized patients to receive cadaveric transplants.
46. Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3:952-960.
47. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4:379-398.
48. Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158:1889-1893.
49. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis Nordic Myeloma Study Group. Eur J Haematol 2000; 65:175-181.
50. Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150:863-869.
51. Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998; 13:1438-1445.
52. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13:79-90.
53. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001; 158:1859-1866.
54. Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed multiple myeloma: a demographic study of 1353 patients The Nordic Myeloma Study Group. Eur J Haematol 1994; 53:207-212.
55. Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001; 56:207-210.
56. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988; 33:1175-1180.
57. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143:777-784. This randomized controlled trial questioned the use of plasmapheresis in patients with acute renal failure due to myeloma.
58. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393-397.
59. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Clinical experience in 108 patients. N Engl J Med 1991; 325:398-403.
60. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
61. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
62. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002; 100:778-785.
63. Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998; 57:293-302.
64. Galbusera M, Noris M, Rossi C, et al. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Blood 1999; 94:610-620.
65. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93:443-452.
66. Bernardo A, Ball C, Nolasco L, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005; 3:562-570. This study delineated further the pathogenesis of TTP and how leukocytes are tethered by ULVWF to the endothelium.
67. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3:1663-1675.
68. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004; 407-423.
69. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68.
70. Byrnes JJ, Moake JL, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990; 34:169-174.
71. Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005; 129:79-86. This study suggested that cryosupernatant does not improve outcome in patients with TTP compared with plasma exchange.
72. Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001; 16:19-22.